Next Generation Immunotherapies Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Expected Next Generation Immunotherapies Market Size During the Forecast Period?
The market size of the upcoming generation immunotherapies has seen substantial growth in the recent past. The market, which will be valued at $133.81 billion in 2024, is projected to increase to $150.54 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 12.5%. The significant growth witnessed during the historical period can be tied to factors such as the growing incidence of oncology, amplified investments in research and development, increased government initiatives, a rise in government health spending, and the expansion of indications.

The market size of next-generation immunotherapies is anticipated to witness rapid expansion in the ensuing years, reaching a value of $238.04 billion in 2029 at a CAGR of 12.1%. Factors contributing to this growth in the projection period include the increasing incidence of cancer, heightened healthcare expenditure, the expanding use of chimeric antigen receptor (CAR) t-cell therapy, the escalating chronic disease burden, and an upturn in research related to next-generation drugs. The forecast period is expected to see trends such as a move towards combination therapies, technological progression, innovation in therapeutic methods, development in personalized medication, and advancements in regulatory support.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21231

What Are the High-Growth Segments in the Next Generation Immunotherapies Market?
The next generation immunotherapies market covered in this report is segmented -

1) By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates - ADC's, Angiotensin-Converting Enzyme (ACE) Inhibitors, Immune Checkpoint Inhibitors
2) By Route Of Administration: Intravenous, Parenteral, Intratumoral, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacies, Clinical Pharmacies, Other Distribution channels

Subsegments:
1) By Monoclonal Antibodies: Anti-PD-1 Antibodies, Anti-PD-L1 Antibodies, Anti-CTLA-4 Antibodies, Anti-CD20 Antibodies, Other Monoclonal Antibodies
2) By Antibody-Drug Conjugates (ADC's): HER2-targeted ADCs, CD30-targeted ADCs, CD19-targeted ADCs, Other ADCs
3) By Angiotensin-Converting Enzyme (ACE) Inhibitors: ACE Inhibitors For Cancer Therapy, ACE Inhibitors For Other Indications
4) By Immune Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Immune Checkpoint Inhibitors

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21231&type=smp

What Key Drivers Are Expected to Influence Future Next Generation Immunotherapies Market Growth?
The escalating incidence of cancer is anticipated to fuel the expansion of the next-generation immunotherapies market. Cancer, a collective term for diverse diseases characterized by the uncontrolled multiplication and spread of abnormal cells in the body, is increasingly prevalent due to causes like ageing populations, changes in lifestyle, environmental exposure, and advanced detection techniques. Next-generation immunotherapies offer superior, precise treatments that boost the body's immune defense against cancer, promising more effectiveness, durability, and customization. For example, National Cancer Institute (NCI), a government agency in the US, reported in May 2024 that there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths worldwide in 2022, forecasting 29.9 million new cases and 15.3 million cancer-related deaths by 2040. Therefore, the growing incidence of cancer is a significant driver for the expansion of the next-generation immunotherapies market.

Which Companies Hold the Largest Share Across Different Next Generation Immunotherapies Market Segments?
Major companies operating in the next generation immunotherapies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Incyte Corporation, BioNTech SE, Xencor Inc., Fate Therapeutics Inc., Immatics N.V., Atara Biotherapeutics Inc., Menarini Group, Alpine Immune Sciences Inc., Mereo Biopharma Group plc, Immunomic Therapeutics Inc., Indaptus Therapeutics Inc.

What Are the Latest Developing Trends in the Next Generation Immunotherapies Market?
Leading enterprises in the next-generation immunotherapies sector are directing their efforts towards spearheading creative treatments like CAR T-cell therapy, geared towards addressing cancers, autoimmune diseases, and infectious diseases. CAR T-cell therapy is a unique genre of immunotherapy wherein a patient's T cells, a variant of immune cells, are genetically programmed to exhibit chimeric antigen receptors (CARs). As a demonstration, Immuneel Therapeutics Private Limited, a cell and gene therapy pioneer from India, introduced India's first-ever CAR T-cell therapy - Qartemi - in January 2025. The therapy, crafted to treat adult B-cell non-Hodgkin lymphoma, genetically alters a patient's immune cells to zero in on and eradicate cancer cells, delivering a highly potent and personal treatment choice. It unveils a renewed beacon of hope to patients who have found no relief in conventional treatments, accompanied by the bonus of being more cost-effective than similar overseas options.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/next-generation-immunotherapies-global-market-report

What Are the Emerging Geographies for The Next Generation Immunotherapies Market Growth?
North America was the largest region in the next-generation immunotherapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation immunotherapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Next Generation Immunotherapies Market?
2. What is the CAGR expected in the Next Generation Immunotherapies Market?
3. What Are the Key Innovations Transforming the Next Generation Immunotherapies Industry?
4. Which Region Is Leading the Next Generation Immunotherapies Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments."

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.